News ReleaseView printer-friendly version << Back
Pacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million
“2016 was a year of solid execution that has set the stage for continued growth of EXPAREL,” said
Preliminary Unaudited 2016 Revenues:
- Total revenues for the fourth quarter of 2016 were
$72.9 million, compared to $69.3 millionfor the fourth quarter of 2015.
- EXPAREL net product sales for the fourth quarter of 2016 were
$71.4 million, compared to $67.2 millionfor the fourth quarter of 2015.
- Total revenues for 2016 were
$276.4 million, compared to $249.0 millionfor 2015.
- EXPAREL net product sales for 2016 were
$265.8 million, compared to $239.9 millionfor 2015.
Mr. Stack continued: “As we look to 2017, we are on track to deliver multiple key milestones including results from our Phase 4 randomized controlled trials in knee and spine, as well as our Phase 3 nerve block studies that are designed to expand the EXPAREL label. We are also planning to initiate a number of Phase 4 randomized controlled trials in soft tissue procedures. With respect to partnerships, we are seeing strong interest from potential partners who share our commitment to broadening the use of EXPAREL as an alternative to opioids in the acute postsurgical setting.”
Pacira will provide final financial results and additional information on the fourth quarter and full-year 2016 performance in the earnings press release and conference call that will take place in the first quarter of 2017.
EXPAREL (bupivacaine liposome injectable suspension) is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain score with up to a 45 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations, plans, outlook and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL and our other products; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of
Susan Mesco(973) 451-4030 firstname.lastname@example.org Media Contact: Coyne Public Relations Alyssa Schneider(973) 588-2270 email@example.com